Tags: Drug.
Ixekizumab is a humanized monoclonal antibody for the treatment of autoimmune diseases. More specifically it is being tested for the use in psoriasis. A Phase II clinical trial including patients with moderate to severe psoriasis has been completed and a Phase III open-label trial is under way as of November 2013.Ixekizumab was developed by Eli Lilly and Co.